Drug Trial Radar · NCT00483886
Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation
Last checked: Nov 20, 2026Latest source record: Apr 11, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
620
Actual
Start
Apr 1998
Primary completion
May 1999
Study completion May 1999
Sponsor
- Lead sponsor
- MovetisIndustry
- Sponsor type
- Industry
- First posted
- Jun 7, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of chronic constipation. Hypothesis: Prucalopride 2 mg and 4 mg given once daily for 12 weeks is superior to placebo for the treatment of patients with chronic constipation and is well tolerated in those patients.
Conditions
- Constipation
Interventions
PrucaloprideDrug
2 mg o.d.
PlaceboOther
Placebo o.d.
PrucaloprideDrug
4 mg o.d.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with an average of 3 or more SCBM per weekTime frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.